30. INVESTIGATION INTO THE EFFECTIVENESS AND SAFETY OF THE BIORESORBABLE ABSORB STENT IN CORONARY ARTERY INTERVENTIONS: A PROSPECTIVE STUDY CONDUCTED AT A SINGLE CENTER
Main Article Content
Abstract
Introduction: In recent years, there have been notable advancements in the diagnosis and treatment of coronary artery disease. Bioresorbable scaffold stents, designed with rigid frames and drug-eluting properties akin to metallic stents, have emerged as a significant innovation in percutaneous coronary intervention. The first generation of bioresorbable stents, exemplified by the Absorb stent, utilizes a Poly-L-lactic acid (PLLA) framework coated with Everolimus, with an average resorption time of 2 to 4 years, aiming to fully absorb to restore vascular function and structure.
Method: A cross-sectional prospective study was conducted on 90 patients undergoing percutaneous coronary intervention using the Absorb stent at the Interventional Cardiology Department of the University Medical Center in Ho Chi Minh City.
Results: Among the total of 90 patients undergoing percutaneous coronary intervention using the Absorb stent, the most prevalent lesion site was the left anterior descending artery, accounting for 67.8% of cases. During in-hospital follow-up, one case of myocardial infarction unrelated to the target lesion treated with the Absorb stent was documented. After 1 year, there were 5 cases of in-stent restenosis, representing 5.6% of cases, and 1 case of myocardial infarction occurring one month post-discharge.
Conclusion: In general, the Absorb stent represents a safe and effective choice for coronary artery intervention. The low use of intravascular ultrasound in the study may also have increased the rate of in-stent restenosis during the 1-year follow-up period. The support of intravascular imaging diagnostic tools is essential for optimizing coronary artery intervention outcomes.
Article Details
Keywords
Percutaneous coronary intervention, Absorb everolimus-eluting bioreabsorbable scaffold
References
III, ABSORB China, and ABSORB Japan", Glob Cardiol Sci Pract, 2015 (5), pp. 62.
[2] Serruys P. W., Chevalier B., Dudek D., et al. (2015), "A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial", Lancet, 385 (9962), pp. 43-54.
[3] Ellis Stephen G., Kereiakes Dean J., Metzger D. Christopher, et al. (2015), "Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease", New England Journal of Medicine, 373 (20), pp. 1905-1915.
[4] Garcia-Garcia Hector M, McFadden Eugène P, Farb Andrew, et al. (2018), "Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document", European Heart Journal, 39 (23), pp. 2192-2207.
[5] Thygesen Kristian, Alpert Joseph S, Jaffe Allan S, et al. (2018), "Fourth universal definition of myocardial infarction (2018)", European Heart Journal, 40 (3), pp. 237-269.